Rockwell Medical Announces Product Purchase Agreement with Leading At-Home and Acute Care Dialysis Provider
Rockwell Medical (Nasdaq: RMTI) has announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States. The company will supply its RenalPure® liquid acid and SteriLyte® liquid bicarbonate hemodialysis concentrates to the customer. These products will be packaged in either four-per-case for larger dialysis settings or two-per-case for smaller acute care and at-home care settings.
Rockwell Medical's convenience pack, which includes two 1-gallon pre-mixed containers of either RenalPure or SteriLyte, offers advantages such as easier handling and streamlined workflow for home patients, caregivers, healthcare providers, and acute facilities. This agreement supports the customer's patient-centric care model and addresses the growing demand for technological advancements in the dialysis space, particularly in the underserved at-home hemodialysis segment.
Rockwell Medical (Nasdaq: RMTI) ha annunciato un accordo per l'acquisto di prodotti con il principale fornitore di dialisi a domicilio e acuta negli Stati Uniti. L'azienda fornirà i suoi concentrati di emodialisi RenalPure® acido liquido e SteriLyte® bicarbonato liquido al cliente. Questi prodotti saranno confezionati in quantità di quattro per confezione per le strutture di dialisi più grandi o due per confezione per le strutture di acute care e assistenza domiciliare più piccole.
Il pacchetto di convenienza di Rockwell Medical, che include due contenitori da 1 gallone pre-miscelati di RenalPure o SteriLyte, offre vantaggi come una gestione più semplice e un flusso di lavoro ottimizzato per i pazienti a domicilio, i caregiver, i fornitori di assistenza sanitaria e le strutture acute. Questo accordo supporta il modello di assistenza centrato sul paziente del cliente e risponde alla crescente domanda di progressi tecnologici nel settore della dialisi, in particolare nel segmento della dialisi a domicilio che è stato trascurato.
Rockwell Medical (Nasdaq: RMTI) ha anunciado un acuerdo de compra de productos con el principal proveedor de diálisis en casa y aguda en Estados Unidos. La empresa suministrará sus concentrados de hemodiálisis RenalPure® ácido líquido y SteriLyte® bicarbonato líquido al cliente. Estos productos se empaquetarán en cuatro por caja para los entornos de diálisis más grandes o en dos por caja para los entornos de atención aguda y cuidado en casa más pequeños.
El paquete de conveniencia de Rockwell Medical, que incluye dos contenedores de 1 galón premezclados de RenalPure o SteriLyte, ofrece ventajas como un manejo más fácil y un flujo de trabajo optimizado para los pacientes en casa, cuidadores, proveedores de atención médica y instalaciones agudas. Este acuerdo apoya el modelo de atención centrado en el paciente del cliente y responde a la creciente demanda de avances tecnológicos en el espacio de la diálisis, particularmente en el segmento de hemodiálisis a domicilio que se ha pasado por alto.
록웰 메디컬 (Nasdaq: RMTI)은 미국의 주요 재택 및 급성 간호 투석 제공업체와 제품 구매 계약을 체결했습니다. 회사는 고객에게 RenalPure® 액체산과 SteriLyte® 액체 중탄산염 혈액 투석 농축액을 공급할 예정입니다. 이 제품들은 대규모 투석 환경을 위한 4개 묶음 또는 소규모 급성 치료 및 재택 치료 환경을 위한 2개 묶음으로 포장됩니다.
록웰 메디컬의 편리한 패키지는 RenalPure 또는 SteriLyte 각각 1갤런의 미리 혼합된 용기 2개를 포함하고 있어 재택 환자, 보호자, 의료 제공자 및 급성 시설을 위한 더 쉬운 취급과 효율적인 작업 흐름의 이점을 제공합니다. 이 계약은 고객의 환자 중심 치료 모델을 지원하고, 특히 재택 혈액 투석 세그먼트에서 기술 발전에 대한 증가하는 수요를 충족시킵니다.
Rockwell Medical (Nasdaq: RMTI) a annoncé un accord d'achat de produit avec le principal fournisseur de dialyse à domicile et à soin aigu aux États-Unis. L'entreprise fournira à son client ses concentrés d'hémodialyse RenalPure® acide liquide et SteriLyte® bicarbonate liquide. Ces produits seront emballés en quatre par boîte pour les grands établissements de dialyse ou en deux par boîte pour les établissements de soin aigu et d'assistance à domicile plus petits.
Le pack de commodité de Rockwell Medical, qui comprend deux contenants de 1 gallon pré-mélangés de RenalPure ou SteriLyte, offre des avantages tels qu'une manipulation plus facile et un flux de travail rationalisé pour les patients à domicile, les aidants, les fournisseurs de soins de santé et les établissements aigus. Cet accord soutient le modèle de soins centré sur le patient du client et répond à la demande croissante pour des avancées technologiques dans le domaine de la dialyse, en particulier dans le segment de l'hémodialyse à domicile qui a été négligé.
Rockwell Medical (Nasdaq: RMTI) hat eine Produktkaufvereinbarung mit dem führenden Anbieter von häuslicher und akuter Dialyse in den Vereinigten Staaten angekündigt. Das Unternehmen wird seine RenalPure® Flüssigsäure und SteriLyte® Flüssigbicarbonat Hämodialysekonzentrate an den Kunden liefern. Diese Produkte werden entweder vier pro Karton für größere Dialyse-Einrichtungen oder zwei pro Karton für kleinere akute Pflege- und häusliche Pflege-Einrichtungen verpackt.
Das Convenience-Paket von Rockwell Medical, das zwei 1-Gallonen-Vormischbehälter von entweder RenalPure oder SteriLyte enthält, bietet Vorteile wie einfachere Handhabung und optimierte Arbeitsabläufe für Patienten zu Hause, Pflegekräfte, Gesundheitsdienstleister und akute Einrichtungen. Diese Vereinbarung unterstützt das patientenzentrierte Versorgungsmodell des Kunden und geht auf die wachsende Nachfrage nach technologischen Fortschritten im Dialysebereich ein, insbesondere im unterversorgten Bereich der häuslichen Hämodialyse.
- Secured product purchase agreement with leading at-home and acute care dialysis provider in the US
- Positioned as preferred provider for liquid acid and liquid bicarbonate hemodialysis concentrates domestically and internationally
- Addressing growing demand in underserved at-home hemodialysis segment
- Offering unique convenience pack for easier handling and streamlined workflow
- None.
Rockwell Medical's new product purchase agreement with a leading at-home and acute care dialysis provider marks a significant step in addressing the growing demand for home-based hemodialysis solutions. The company's RenalPure® and SteriLyte® concentrates, packaged in convenient two-per-case formats, cater to the underserved at-home hemodialysis segment. This move aligns with the industry trend towards patient-centric care models and technological advancements in dialysis.
The convenience pack's advantages, including easier handling and streamlined workflow, could potentially improve patient adherence and quality of life. For healthcare providers, this could translate to reduced costs and improved efficiency in both acute care and home settings. However, the impact on Rockwell Medical's revenue and market share remains to be seen, as it will depend on the scale of implementation and patient adoption rates.
This agreement positions Rockwell Medical favorably in the rapidly growing home dialysis market. The global home dialysis market is projected to reach
The convenience pack addresses key pain points in home dialysis, potentially increasing patient adoption. However, challenges remain, including patient education, training and reimbursement policies. The success of this venture will largely depend on how effectively these barriers are addressed. Investors should monitor key performance indicators such as product uptake rates, customer retention and revenue growth in the coming quarters to gauge the impact of this agreement on Rockwell Medical's financial health.
While the agreement signifies a positive development for Rockwell Medical, investors should approach with cautious optimism. The financial impact will depend on the volume of products supplied and the duration of the agreement, details which are not disclosed. It's important to note that Rockwell Medical reported a net loss of
The at-home dialysis market presents significant growth opportunities, but it's a competitive landscape with established players. Rockwell's success will hinge on its ability to scale production, manage costs and maintain quality. Investors should closely monitor upcoming financial reports for indications of revenue growth and margin improvements resulting from this agreement. The stock may see short-term positive sentiment, but long-term performance will depend on tangible financial results.
Provides Customer with the only hemodialysis concentrates convenience pack in the dialysis marketplace to support its at-home and acute care patient populations
"This customer has a leading patient-centric care model that addresses the increasing demand for technological advancements in the dialysis space," said Tim Chole, Chief Commercial Officer at Rockwell Medical. "The underserved at-home hemodialysis segment presents an exciting evolution, offering patients an alternative to traveling, in many instances, several hours, multiple times a week to receive their life-sustaining hemodialysis treatments. We are pleased to be this Customer's preferred provider domestically and internationally for liquid acid and liquid bicarbonate hemodialysis concentrates products. Additionally, we are proud to support this Customer's vision to transform the dialysis experience for patients and make dialysis available anytime, anywhere."
Rockwell Medical's convenience pack includes two 1-gallon pre-mixed containers of one of the Company's hemodialysis concentrates products, RenalPure or SteriLyte, offering a number of advantages for home patients, caregivers, healthcare providers, and acute facilities including easier handling and streamlined workflow. For more information, visit www.rockwellmed.com/hemodialysis-products.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will become the leading global supplier of hemodialysis concentrates. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909835914/en/
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockwellMed.com
Source: Rockwell Medical, Inc.
FAQ
What products will Rockwell Medical (RMTI) supply under the new agreement?
How are Rockwell Medical's (RMTI) products packaged for different care settings?
What advantages does Rockwell Medical's (RMTI) convenience pack offer?
Which market segment is Rockwell Medical (RMTI) targeting with this agreement?
